What is AMRN's current stock price?

AMRN (Amarin Corporation plc) is currently trading at $14.38 with a market cap of $297.4M.

What sector is Amarin Corporation plc in?

Amarin Corporation plc (AMRN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AMRN a good stock to buy?

Analysts have a Sell consensus on AMRN with a price target of $2.17. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AMRN Amarin Corporation plc

Healthcare

$14.38+0.00%OpenMarket Cap: $297.4M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.67

P/S

1.39

EV/EBITDA

-76.65

DCF Value

$-20.03

FCF Yield

8.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.5%

Operating Margin

-17.4%

Net Margin

-15.6%

ROE

-7.3%

ROA

-5.2%

ROIC

-7.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$43.3M	$-10.5M	$—
Q4 null	$49.1M	$-1.2M	$—
FY null	$213.6M	$-38.8M	$—
Q3 null	$49.7M	$-7.7M	$—

Analyst Ratings

View All

Consensus

Sell

Target (Consensus)

$2.17

Target (Median)

$2.00

Target Range

$1.50 - $3.00

0 Strong Buy0 Buy1 Hold1 Sell0 Strong Sell

Goldman SachsSell

2025-06-25

Trading Activity

Insider Trades

View All

Bonfiglio Patrice Eadondirector

SellWed Apr 22

Bonfiglio Patrice Eadondirector

SellWed Apr 22

Sullivan Diane E.director

SellTue Apr 21

Sterling Louis IIIdirector

SellTue Apr 21

Sterling Louis IIIdirector

SellTue Apr 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.82

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Peers

ALT